Skip to main content
. 2015 Jul 2;5:11747. doi: 10.1038/srep11747

Figure 2. Screening and functional evaluation of mdr1a siRNA in vitro and in vivo.

Figure 2

(a) RNAi-mediated knockdown of mdr1a mRNA in CT26.WT cells. (b) RNAi-mediated knockdown of P-gp protein in CT26.WT cells. CT26.WT cells were transfected with mdr1a siRNAs. After 48 h, mRNA for mdr1a gene and P-gp protein expression were measured by real-time PCR and western blot. (c) RNAi-mediated knockdown of P-gp protein expression in liver of mice. mdr1a-1 siRNA (at a dose of 5, 10, 15 nmol) was injected via the tail vein of mice. After 48 h, the livers of mice were collected and the P-gp protein expression was measured to validate the efficacy of siRNA. (d) Evaluation of P-gp function after pretreatment with mdr1a-1 siRNA in mice. The NC-siRNA or mdr1a-1 siRNA (15 nM) was intravenously injected 2 days prior to the digoxin injection at a dose of 1 mg/kg. The blood samples were collected at scheduled time intervals. Data are presented as mean ± SD (n = 3 in vitro and n = 5 in vivo). #P < 0.05, ##P < 0.01, ###P < 0.001 compared with NC-siRNA group.